Though used as a first-line therapy, intervening RAS at the level of ACE or AT1 receptors in renal patients is shown not to consistently reduce proteinuria, which is not only a powerful predictor but also a promoter of renal dysfunction; this is true for the dosages recommended for hypertension control and even for supramaximal dosages [49]. Here, ACE is linked to hypertensive disorder.